1643. Immunizing Patients with Adverse Events Following Immunization in the Canadian Special Immunization Clinic Network (2015–2017)
Session: Poster Abstract Session: Vaccine Strategy and Policy
Friday, October 6, 2017
Room: Poster Hall CD
Posters
  • IDWeek SIC AEFI poster Sept29.pdf (708.3 kB)
  • Background:

    The experience of an adverse event following immunization (AEFI) can increase vaccine hesitancy among patients and health professionals who may be concerned about the risk of a recurrent or more severe event following revaccination. Infectious disease physicians and allergists in the Canadian Special Immunization Clinic (SIC) Network developed standard protocols for evaluation and revaccination of patients with prior AEFIs. We analyzed the outcomes of patients evaluated for AEFIs from 2015 to 2017.

    Methods:

    Patients are referred to one of 11 SICs in Canada by a physician or Public Health. Inclusion criteria are: patients of any age with injection-site reaction (ISR) ≥10 cm, allergic-like events (ALE) <24h post-immunization, neurological symptoms, and other AEFIs of concern. SIC physicians evaluate eligible patients and make immunization recommendations according to standard protocols. Patients are followed up after revaccination to capture AEFI recurrence. Recommendations and outcomes of revaccination(s) are transmitted to referring providers and Public Health. Following individual consent, data are transferred to a central database for analysis. For patients with more than one AEFI, the most severe event was included in the analysis.

    Results:

    From June 2015 to May 2017, 230 patients were referred to the network for prior AEFI and 124 patients were enrolled. Most participants (86%) were <18 years of age and 49% were female. The most common types of AEFI were ALEs (37%; 46/124), followed by ISRs (23%; 29/124), neurologic events (15%; 19/124), and other systemic events (e.g., high fever) (24%; 30/124). Revaccination was recommended for 89 (72%) patients. AEFI recurrences occurred in 9/63 (14%) patients who were revaccinated and followed up: 2/22 (9%) ALEs (both less severe than first AEFI) and 7/14 (50%) ISRs (5 less severe, 2 equally severe as first AEFI).

    Conclusion:

    Patients with AEFIs benefit from clinical assessment by physicians with expertise in vaccines. The results suggest that most AEFIs do not contraindicate future immunizations. The risk of AEFI recurrence is low, except for ISRs, which are generally less severe that the initial AEFI. Specialized immunization services can support health professionals in managing patients with prior AEFIs.

    Karina A Top, MD, MS1, Francois D Boucher, MD2,3, Athena McConnell, MD4,5, Jeffrey Pernica, MD, MSc, FRCPC6, Anne Pham-Huy, MD7,8, Wendy Vaudry, MD9, Shelley L Deeks, MD, MHSc10, Francisco Noya, MD11, Bruce Tapiero, MD12, Caroline Quach, MD, MSc12, Dat Tran, MD, MS13, Shaun K Morris, MD, MPH, FRCPC, FAAP, DTM&H14, Simon Dobson, MA, MBBS, MD15, Manish Sadarangani, BM, BCh, DPhil16, Shelly A McNeil, MD, FIDSA17, Donna MacKinnon-Cameron, MSc17, Lingyun Ye, MSc17, Scott A. Halperin, MD1 and Gaston De Serres, MD18, (1)Dalhousie University IWK Health Centre, Halifax, NS, Canada, (2)Centre hospitalier universitaire de Québec, Quebec, QC, Canada, (3)Laval University, Quebec, QC, Canada, (4)Royal University Hospital, Saskatoon, SK, Canada, (5)University of Saskatchewan, Saskatoon, SK, Canada, (6)Pediatrics, McMaster University, Hamilton, ON, Canada, (7)University of Ottawa, Ottawa, ON, Canada, (8)Children’s Hospital of Eastern Ontario, Ottawa, ON, Canada, (9)The University of Alberta, Edmonton, AB, Canada, (10)Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, (11)McGill University Health Centre Research Institute, Montreal, QC, Canada, (12)Centre hospitalier universitaire Ste-Justine, Montreal, QC, Canada, (13)The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, (14)Division of Infectious Diseases, Department of Paediatrics, The Hospital for Sick Children, Toronto, ON, Canada, (15)BC Children's Hospital Research Institute, University of British Columbia, Vancouver, BC, Canada, (16)Vaccine Evaluation Center, British Columbia Children's Hospital, University of British Columbia, Vancouver, BC, Canada, (17)Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax, NS, Canada, (18)Laval University, Quebec City, QC, Canada

    Disclosures:

    K. A. Top, Pfizer: Investigator , Research support
    GSK: Investigator , Research grant

    F. D. Boucher, None

    A. McConnell, None

    J. Pernica, None

    A. Pham-Huy, None

    W. Vaudry, None

    S. L. Deeks, None

    F. Noya, None

    B. Tapiero, None

    C. Quach, None

    D. Tran, None

    S. K. Morris, None

    S. Dobson, None

    M. Sadarangani, Pfizer: Grant Investigator , Research grant

    S. A. McNeil, GSK/Merck: Grant Investigator , Investigator and Scientific Advisor , Consulting fee , Grant recipient , Research grant , Research support and Speaker honorarium

    D. MacKinnon-Cameron, None

    L. Ye, None

    S. A. Halperin, None

    G. De Serres, GlaxoSmithKline: Investigator and Scientific Advisor , Grant recipient and travel reimbursement
    Ontario Nurses Association: Consultant , compensation for expert testimony

    Previous Abstract | Next Abstract >>

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.